10.08.2011 • NewsMyriadQ4 2011sales and profits

Myriad Genetics Q4 Profit Falls

Myriad Genetics reported net income for the fourth quarter of $26.0 million or $0.30 per share, compared to $53.3 million or $0.54 per share for the year-ago quarter.

The latest quarter results include a $16.1 million income tax expense recorded for accounting purposes, while the year-ago quarter results included no tax expense and a one-time income tax benefit of $14.6 million.

Total revenue for the fourth quarter rose to $107.41 million from $93.93 million a year earlier.

Analysts polled by Thomson Reuters expected the company to earn $0.29 per share on revenue of $104.43 million for the fourth quarter.

For fiscal year 2012, the company forecast total revenue of $445 million to $465 million and earnings of $1.20 to $1.25 per share. Analysts currently expect the company to earn $1.26 per share on revenue of $453.80 million for the fiscal year 2012.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.